Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
CKD-MBD is formerly defined by the KDIGO as a systematic disease of mineral and bone metabolism due to CKD, marked by biochemical disturbances in calcium, phosphate, parathyroid hormone (PTH), and vitamin D metabolism. These abnormalities impair bone strength and promote vascular calcification, increasing fracture and cardiovascular risk. Early stages of CKD (3 and 4) provide an important opportunity for detection and intervention. While biochemical markers remain standard, bone mineral density (BMD) assessment with dual-energy X-ray absorptiometry (DEXA) offers an objective evaluation of skeletal health. Data on Indian pre-dialysis populations remain limited.
A single-centre, prospective observational study was conducted at Gauhati Medical College between May 2024 and April 2025. A total of 130 pre-dialysis CKD patients (Stage 3: n=72; Stage 4: n=58) were enrolled. Clinical details, biochemical parameters and BMD were analysed. BMD categories were classified as normal, osteopenia, or osteoporosis according to WHO criteria. Patients on maintenance hemodialysis, CAPD and renal transplant recipients were excluded from the study. Statistical significance was defined as p<0.05.
The mean age was 47.9 ± 14.3 years; 59.2%were male. Diabetic nephropathy (33.8%) was the leading cause of CKD. Compared to Stage 3, Stage 4 patients had significantly higher creatinine (2.86 ± 0.46 vs 1.90 ± 0.29 mg/dL, p<0.001), lower vitamin D (21.4 ± 6.8 vs 32.2 ± 7.6 ng/mL, p<0.0001), higher iPTH (329.7 ± 92.2 vs 274.2 ± 84.1 pg/mL, p=0.0006), and higher phosphate levels (p=0.0011). DEXA revealed lower T-scores in Stage 4 at all sites (p≤0.0004). Osteoporosis prevalence was 44.8% in Stage 4 versus 18.1% in Stage 3 (p=0.0014).
CKD-MBD begins early in stages 3 and 4, with progressive biochemical derangements and significant bone loss. DEXA adds value to biochemical markers in detecting skeletal involvement, and integrated monitoring can aid early diagnosis and intervention in pre-dialysis CKD patients. These findings underscore the need for early recognition and proactive management of mineral abnormalities beginning in mid stage CKD .By intervening before advanced kidney failure nephrologists can mitigate fracture risk and imorove long term outcomes.
